Kinetic study of the degradation of forskolin in aqueous systems by stability-indicating HPLC method and identification of its degradation products

Development of the Forskolin Microemulsion Formula and its Irritation Test on Rabbits

Objectives

This study aimed to develop a microemulsion formula that can increase the solubility and stability of forskolin and its safety for topical use.

Materials and Methods

The materials used for the development of the microemulsion formula were triglyceride oil, non-ionic surfactants, and polyethylene glycol (PEG) for cosurfactants, which were selected on the basis of the results of the forskolin solubility test using high performance liquid chromatography (HPLC). The microemulsion was formulated by the phase titration method. Formula stability was determined by storage for 90 days in a refrigerator at room temperature, and an accelerated stability test was performed by determining globule size, forskolin concentration, and pH. The safety of using microemulsions was determined by skin irritation tests on albino rabbits.

Results

The optimum microemulsion formula consisted of Maisine® CC, polyoxyethylene sorbitan 20 (POE 20), and PEG 400 with a ratio of 4:25:5 w/v, which increased the solubility of forskolin the most, namely 2.19 mg mL-1. Based on globule size (<50 nm), forskolin concentration (2 mg.mL-1), and pH (6.0-6.35), the formula was stable in refrigerator storage and room temperature but unstable in the accelerated stability test (40 °C) starting on day 21. This optimum formula exhibits a primary irritation index (PII) of 0.11, which is categorized as feeble irritation and can be ignored.

Conclusion

The microemulsion prepared by the phase titration method containing Maisine® CC, POE 20, and PEG 400 (4:25:5, w/v) as a base and 0.2% forskolin was stable in refrigerator storage and at room temperature. This microemulsion is mild or negligible irritant with a PII: 0.11.

Long-term application of cannabinoids leads to dissociation between changes in cAMP and modulation of GABAA receptors of mouse trigeminal sensory neurons

Antinociception caused by cannabinoids may have a partial peripheral origin in addition to its central site of action. In fact, we have observed that anandamide selectively and reversibly inhibits GABA_A receptors of putative nociceptive neurons of mouse trigeminal sensory ganglia via CB1 receptor activation to inhibit adenylyl cyclase and decrease cAMP with downstream posttranslational alterations. Since cannabinoids are often used chronically, we studied changes in cAMP levels and GABA-mediated currents of trigeminal neurons following 24 h application of anandamide (0.5 μM) or the synthetic cannabinoid WIN 55,212-2 (5 μM). With this protocol GABA responses were similar to control despite persistent fall in cAMP levels. Inhibition by WIN 55,212-2 of GABA effects recovered after 30 min washout and was not associated with changes in CB1 receptor expression, indicating lack of CB1 receptor inactivation and transient loss of negative coupling between CB1 receptors and GABA_A receptors. The phosphodiesterase inhibitor rolipram (100 μM; 24 h) enhanced cAMP levels and GABA-mediated currents, suggesting GABA_A receptors were sensitive to persistent upregulation via cAMP. While the adenylyl cyclase activator forskolin (1-20 μM) facilitated cAMP levels and GABA currents following 30 min application, this action was lost after 24 h in line with the drug limited lifespan. The PKA inhibitor PKI 14-22 (10 μM) increased cAMP without changing GABA currents. These data indicate that modulation of GABA_A receptors by intracellular cAMP could be lost following persistent application of cannabinoids. Thus, these observations provide an insight into the waning antinociceptive effects of these compounds.